Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00670267Phase 1Completed

Oral Nadolol for the Treatment of Adults With Mild Asthma

Role: collaborator

NCT00671229Completed

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1

Role: collaborator

NCT00643058Phase 1Terminated

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II

Role: collaborator

All 3 trials loaded